IPD Stock Overview
A medical technology company, manufactures, and sells bioimpedance spectroscopy (BIS) technology medical devices in the Unites States and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ImpediMed Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.055 |
| 52 Week High | AU$0.16 |
| 52 Week Low | AU$0.042 |
| Beta | 2.87 |
| 11 Month Change | -3.51% |
| 3 Month Change | 1.85% |
| 1 Year Change | -59.26% |
| 33 Year Change | -67.65% |
| 5 Year Change | -67.65% |
| Change since IPO | -93.53% |
Recent News & Updates
Recent updates
We Think ImpediMed (ASX:IPD) Can Afford To Drive Business Growth
Jun 26
ImpediMed (ASX:IPD) Is In A Good Position To Deliver On Growth Plans
Mar 05Companies Like ImpediMed (ASX:IPD) Are In A Position To Invest In Growth
Nov 23Is ImpediMed (ASX:IPD) In A Good Position To Deliver On Growth Plans?
Jul 11We Think ImpediMed (ASX:IPD) Needs To Drive Business Growth Carefully
Mar 27Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation
Sep 28We're Not Worried About ImpediMed's (ASX:IPD) Cash Burn
Jun 10A Look At The Fair Value Of ImpediMed Limited (ASX:IPD)
Feb 01Shareholder Returns
| IPD | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | 3.8% | 0.5% | 0.9% |
| 1Y | -59.3% | 14.8% | 18.4% |
Return vs Industry: IPD underperformed the Australian Medical Equipment industry which returned 13.5% over the past year.
Return vs Market: IPD underperformed the Australian Market which returned 17.7% over the past year.
Price Volatility
| IPD volatility | |
|---|---|
| IPD Average Weekly Movement | 10.1% |
| Medical Equipment Industry Average Movement | 9.3% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.3% |
Stable Share Price: IPD has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: IPD's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 83 | Parmjot Bains | www.impedimed.com |
ImpediMed Limited, a medical technology company, manufactures, and sells bioimpedance spectroscopy (BIS) technology medical devices in the Unites States and Europe. The company offers SOZO, a noninvasive BIS device for the clinical assessment of lymphedema and deliver snapshot of fluid status and tissue composition; L-Dex analysis for lymphedema; BodyComp Analysis, a point-of-car body composition analysis; and HF-Dex analysis for point-or care heart failure fluid assessment. It also provides SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications.
ImpediMed Limited Fundamentals Summary
| IPD fundamental statistics | |
|---|---|
| Market cap | AU$111.30m |
| Earnings (TTM) | -AU$19.79m |
| Revenue (TTM) | AU$10.32m |
10.8x
P/S Ratio-5.6x
P/E RatioIs IPD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IPD income statement (TTM) | |
|---|---|
| Revenue | AU$10.32m |
| Cost of Revenue | AU$1.31m |
| Gross Profit | AU$9.01m |
| Other Expenses | AU$28.80m |
| Earnings | -AU$19.79m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0098 |
| Gross Margin | 87.27% |
| Net Profit Margin | -191.78% |
| Debt/Equity Ratio | 0% |
How did IPD perform over the long term?
See historical performance and comparison